Swipe Left For English News
苏州，
2026年3月12日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics，2269.HK）与以AI为驱动研发新一代创新生物药的生物科技公司Earendil Labs今日共同宣布，双方签署战略合作协议，药明生物将为Earendil Labs管线中多款用于治疗自身免疫性疾病、肿瘤等疾病的双特异性/多特异性抗体及抗体偶联药物（ADC）提供一体化开发与生产服务。
药明生物首席执行官陈智胜博士（左）与Earendil Labs 首席执行官彭健博士（右）签署战略合作协议
根据协议，药明生物将提供一体化生物药开发与生产服务，包括细胞株开发、工艺与生物分析方法开发、制剂开发以及GMP生产。此次合作旨在加速法规申报进程、提升CMC执行的稳定性与效率，支持Earendil Labs多个项目的全球临床开发。
药明生物在复杂生物药领域持续积累领先优势，特别是在双特异性/多特异性抗体及ADC开发方面的深厚技术积累。截至2025年，药明生物CRDMO一体化平台共承载 945个综合项目，其中双特异性/多特异性抗体已成为增长最快的品类之一。公司依托多项行业领先的创新技术平台——包括基于定点整合（TI）技术的CHO细胞株平台WuXia™ TrueSite、高浓度制剂开发平台WuXiHigh™，以及适用于高剂量与皮下给药的透明质酸酶共制剂平台和大剂量给药装置解决方案，为客户提供从早期研究到商业化生产全流程高效、稳定且可规模化的开发路径。
陈智胜博士
首席执行官
药明生物
我们非常高兴与Earendil Labs达成此次战略合作。Earendil Labs在新一代免疫疗法领域具备突出优势与创新力。凭借我们在复杂生物药，特别是双/多抗及ADC领域积累的深厚经验，以及覆盖整个药物研发及生产的领先技术平台，我们期待加速其创新管线的进程，加快开发，确保稳健规模化生产，共同推动更多突破性疗法惠及全球患者。
彭 健 博士
首席执行官
Earendil Labs
与药明生物的合作，将有助于我们以更高的效率、更高的精度和更高的CMC质量推进管线开发。借助药明生物在复杂生物药开发与生产方面的深厚经验及其端到端一体化能力，并结合 Earendil 在 AI 驱动蛋白工程方面的技术优势，我们能够更快推动项目迈向关键临床里程碑，加速将真正具备临床价值的创新药物带给患者。
朱 祯 平 博士
总裁兼联席CEO
Earendil Labs
过去三年，Earendil Labs 已打造出稳健且极具竞争力的研发管线。此次与药明生物达成合作，将进一步助力我们将AI驱动的创新成果，转化为高质量的临床及商业化产品。药明生物在复杂生物药研发与全球化领域具备深厚经验与专业实力，是我们构建差异化、多元化治疗管线、致力于攻克多种人类疾病的关键战略合作伙伴。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国、新加坡和卡塔尔拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2025年12月底，药明生物帮助客户研发和生产的综合项目高达945个，其中包括74个临床III期项目，25个商业化生产项目。
药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com。
关于Earendil Labs
Earendil Labs是一家以人工智能为驱动的生物科技公司，专注于研发用于治疗自身免疫性疾病、癌症及其他未满足医疗需求的下一代创新生物药。通过融合先进的机器学习、生成式蛋白质工程与高通量实验技术，Earendil Labs及其关联公司华深智药致力于优化药物发现与研究流程，以显著加速药物开发进程。
Earendil Labs自主研发的一体化集成平台，能够精准优化蛋白质类生物制剂的功能性、可生产性与可开发性，使其具备首创新药和/或同类最佳药物的潜力。
更多信息，请查询：www.earendil.bio
业务垂询
info@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics and Earendil Labs Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs
Suzhou,
March 12, 2026
WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today jointly announced the signing of a strategic collaboration agreement on the development and manufacturing of multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs' pipeline targeting autoimmune disease, cancer and other diseases.
Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to accelerate regulatory timelines, enhance CMC execution reliability, and support scalable global clinical development across Earendil Labs' programs.
WuXi Biologics has built a strong track record in developing complex biologics, particularly its technology strengths in bispecific and multispecific antibodies and ADCs.
By 2025, a total of 945 projects were advancing on the company’s integrated CRDMO platform, with bispecific and multispecific antibodies representing one of the fastest‑expanding categories. Leveraging next‑generation technology platforms such as the WuXia™ TrueSite targeted‑integration CHO cell line platform and the WuXiHigh™ high‑throughput formulation platform—together with expanded capabilities for high‑dose and subcutaneous delivery, including the Hyaluronidase Co‑Formulation platform and large‑volume device solutions—the company provides development pathways designed to increase efficiency, strengthen product consistency, and enable seamless scale‑up from early research through commercial manufacturing.
Dr. Chris Chen
CEO
WuXi Biologics
We are delighted to enter this strategic collaboration with Earendil Labs, a company distinguished by its strong scientific leadership and innovative approach to advancing next generation immunotherapies. By leveraging our proven expertise across complex biologics—including bispecific and multispecific antibodies as well as ADCs—and our industry leading technology platforms across drug research, development and manufacturing, we aim to accelerate the advancement of Earendil Labs' innovative pipeline. Through this collaboration, we are poised to accelerate development, ensure robust and scalable manufacturing, and ultimately bring transformative therapies to patients worldwide.
Dr. Jian Peng
CEO
Earendil Labs
Partnering with WuXi Biologics enables us to advance our pipeline with greater speed, precision, and CMC excellence. By integrating Earendil Labs' AI-driven protein‑engineering capabilities with WuXi Biologics' deep expertise in complex biologics as well as its proven end‑to‑end development and manufacturing capabilities, we can more efficiently advance our pipeline toward clinical milestones to deliver meaningful clinical benefit and transform patient treatment.
Dr. Zhenping Zhu
President & Co-CEO Earendil Labs
Earendil Labs has built a robust and highly competitive pipeline within the past three years. This partnership with WuXi Biologics strengthens our ability to translate AI-driven innovation into high-quality clinical and commercial assets. WuXi Biologics' proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset therapeutic pipeline for the treatment of various human diseases.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
About
Earendil Labs
Earendil Labs is an AI-powered biotech company focusing on researching and developing next-generation innovative biologics for the treatment of autoimmune, cancer and other diseases of unmet medical needs. By combining advanced machine learning, generative protein engineering, and high-throughput experimental techniques, Earendil Labs and its affiliate Helixon Therapeutics streamline drug discovery & research process with aim of significantly accelerating drug development.
Earendil Labs' proprietary integrated framework enables precise optimization of functionality, manufacturability, and developability of protein-based biologics with first-in-class and/or best-in-class potential.
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间接收药明生物最新动态
